Allogene Therapeutics (ALLO) Retained Earnings: 2019-2025
Historic Retained Earnings for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$2.0 billion.
- Allogene Therapeutics' Retained Earnings fell 12.05% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 12.05%. This contributed to the annual value of -$1.8 billion for FY2024, which is 16.49% down from last year.
- Latest data reveals that Allogene Therapeutics reported Retained Earnings of -$2.0 billion as of Q3 2025, which was down 2.14% from -$1.9 billion recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Retained Earnings registered a high of -$679.4 million during Q1 2021, and its lowest value of -$2.0 billion during Q3 2025.
- Over the past 3 years, Allogene Therapeutics' median Retained Earnings value was -$1.7 billion (recorded in 2024), while the average stood at -$1.7 billion.
- Data for Allogene Therapeutics' Retained Earnings shows a maximum YoY crashed of 50.78% (in 2021) over the last 5 years.
- Over the past 5 years, Allogene Therapeutics' Retained Earnings (Quarterly) stood at -$894.6 million in 2021, then crashed by 38.05% to -$1.2 billion in 2022, then fell by 26.50% to -$1.6 billion in 2023, then dropped by 16.49% to -$1.8 billion in 2024, then dropped by 12.05% to -$2.0 billion in 2025.
- Its Retained Earnings was -$2.0 billion in Q3 2025, compared to -$1.9 billion in Q2 2025 and -$1.9 billion in Q1 2025.